Neues Anwendungsgebiet: Atopische Dermatitis, 12 bis < 18 Jahre
G-BA action
final resolution
2023-12-21
Evidence-checked summary
The G-BA issued a final resolution on 2023-12-21. The official page states that it took effect as follows: 21.12.2023. The page lists Arzneimittel-Richtlinie, Anlage XII: Nutzenbewertung nach § 35a SGB V as the normative target.
This is the latest validated public action attached to this case. It is separate from the IQWiG assessment result.
Final benefit result
Patient group
Jugendliche von 12 bis 17 Jahren mit mittelschwerer bis schwerer atopischer Dermatitis, die für eine kontinuierliche systemische Therapie in Frage kommen
Added benefit not proven
Comparator
Dupilumab (ggf. in Kombination mit topischen Glukokortikoiden (TCS) und/oder topischen Calcineurininhibitoren (TCI))
Official case record
No inferred stages
Consultation record
2023-03-27
23 parsed turns
Oral hearing: Tralokinumab (Neues Anwendungsgebiet: Atopische Dermatitis, 12 bis < 18 Jahre)
Official Wortprotokoll · 7 pages
IQWiG comparison
IQWiG assessment findings and the later G-BA action are separate records. Open both to compare them.
A22-121
matched
Tralokinumab (moderate-to-severe atopic dermatitis in adolescents) – Benefit assessment according to § 35a Social Code Book V
Official assessment PDF · 37 pages
G-BA decisions
2023-05-12
final resolution
The G-BA found no proven added benefit for Jugendliche von 12 bis 17 Jahren mit mittelschwerer bis schwerer atopischer Dermatitis, die für eine kontinuierliche systemische Therapie in Frage kommen. The appropriate comparator was Dupilumab (ggf. in Kombination mit topischen Glukokortikoiden (TCS) und/oder topischen Calcineurininhibitoren (TCI)). The G-BA issued a final resolution on 2023-05-12. The official page states that it took effect as follows: 12.05.2023. The page lists Arzneimittel-Richtlinie, Anlage XII: Nutzenbewertung nach § 35a SGB V as the normative target.
3 official documents · 4 cited claims
2023-12-21
final resolution
The G-BA issued a final resolution on 2023-12-21. The official page states that it took effect as follows: 21.12.2023. The page lists Arzneimittel-Richtlinie, Anlage XII: Nutzenbewertung nach § 35a SGB V as the normative target.
4 official documents · 3 cited claims
Official sources